Details of the Drug Reposition

General Information of This Drug (ID: DMHJV0X)

Drug Name
Pertuzumab   DMHJV0X
Synonyms Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Adrenal gland neoplasm DISFK7RF N.A. Approved [1]
Breast cancer DIS7DPX1 2C60-2C65 Approved [2]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple endocrine neoplasia DISZGBKW N.A. Withdrawn [3]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroendocrine neoplasm DISNPLOO N.A. Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroblastoma DISVZBI4 2D11.2 Investigative [1]
------------------------------------------------------------------------------------

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
3 Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
4 High Dose Oral 4-Aminosalicylic Acid (PASER) to Control Acute Flares of Mild to Moderate Crohn's Disease